Categories: CancerNews

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1×1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com

Staff

Recent Posts

Semler Scientific® Announces Additional Bitcoin Purchases

SANTA CLARA, Calif., June 6, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer…

6 hours ago

Orange County Soccer Club Taps GENEFIT for Comprehensive Genes-Based Performance and Recovery Insights

The sports-tech innovator powered by 3X4 Genetics will work closely with OCSC coaching, training, and…

6 hours ago

PHTI Study Confirms Positive Clinical and Economic Outcomes for Physical Therapist-Guided Virtual MSK Solutions, Including RecoveryOne

WALNUT CREEK, Calif., June 6, 2024 /PRNewswire/ -- RecoveryOne, a leading virtual musculoskeletal (MSK) care provider…

6 hours ago

Notification of Data Security Incident Best Health Physical Therapy, LLC

GROTON, Conn., June 6, 2024 /PRNewswire/ -- On February 26, 2024, Best Health Physical Therapy,…

6 hours ago

NextSense Honored as World Economic Forum Technology Pioneer

MOUNTAIN VIEW, Calif., June 6, 2024 /PRNewswire/ -- NextSense is proud to announce that it…

6 hours ago